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The long-term outcome of chronic epilepsy remains largely unknown, despite a long historical experience. We report the lifelong
course of epilepsy of an historical cohort of 235 subjects who were in residential care at the Chalfont Centre for Epilepsy: 122
had comprehensive post-mortem examination. The populations admitted as resident to the centre over time followed the
evolution of society’s perception of epilepsy. ‘Early residents’ (before 1972) were admitted for sheltered employment, escaping
stigmatization, whereas ‘later’ residents with more severe epilepsies were admitted for care. Subjects admitted before 1972 were
similar to subjects followed nowadays as outpatients, whereas patients admitted later with a higher burden of disabilities are
often those in residential care. This long follow-up allowed exploration of a wide spectrum of epilepsies, affecting both subjects
who were otherwise healthy and those with co-morbidities. Age at death showed a bimodal distribution with an early peak of
mortality between 45–50 years old, whilst the remainder had life expectancy comparable to the general population. As a group,
subjects who had post-mortem examination were not significantly different from patients who did not have post-mortem
examination, but post-mortem examination provided data that were otherwise unavailable. For those who had post-mortem
examination, sudden unexpected death in epilepsy (SUDEP, 18% of all deaths) did not fully explain the early mortality, to which
co-morbidities contributed. High seizure frequency was a significant independent predictor of early death even after excluding
SUDEP (e.g. reduction in years of life for those who had 44 seizures/month compared with those who had 51 seizure/month:
13 years; 95% confidence interval: 6–19; overall P = 0.0006). Those who survived to older age increasingly went into spon-
taneous remission lasting until death (in the whole cohort, 38/166, 23% of those who died in or after sixth decade). In subjects
who had post-mortem examination, older age (odds ratio = 1.13; 95% confidence interval: 1.06–1.20) and presence of neuro-
pathologically confirmed degenerative changes (that were not the cause of epilepsy) (odds ratio 7.14; 1.95–26.2) were inde-
pendent predictors of terminal remission. Epilepsy may cause premature death indirectly through co-morbid conditions.
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Terminal remission occurs even without prior remissions; ageing may improve epilepsy drug responsiveness although unknown
factors related to the natural history may also play a role.
Keywords: mortality; SUDEP; co-morbidities; remission; age; drug-resistant epilepsy
Abbreviation: SUDEP = sudden unexpected death in epilepsy
Introduction
Chronic epilepsy affects up to a third of subjects with epilepsy but
accounts for most of its overall burden (Jacoby et al., 1998).
Numerous treatment approaches (Shorvon, 2009a, b) have been
employed to tackle this problem throughout history, accompanied
by different social attitudes (Barclay, 1992). Despite this extensive
historical experience, little is known about the long-term outcome
of chronic epilepsy and the effect of ageing on active epilepsy. In
this historical context, post-mortem examination, despite being
decreasingly undertaken (Roberts, 1978), can provide an assess-
ment of structural abnormalities associated with epilepsy and
cause of death, for which MRI cannot act as a complete surrogate.
Previous post-mortem studies, however, have been either small or
lacking clinical correlations (Corsellis, 1957; Margerison and
Corsellis, 1966; Meencke and Janz, 1984).
Chronic epilepsy is considered a lifelong condition, even if per-
iods of remission occur (Luciano and Shorvon, 2007; Callaghan
et al., 2011; Neligan et al., 2011b). It has also been shown to
shorten life expectancy, mostly early after onset (Gaitatzis et al.,
2004b), but also in the long-term (Neligan et al., 2011a). Causes
of death have, however, rarely been investigated with post-
mortem examination. Heterogeneity of epilepsy is barely con-
sidered, prognosis of specific syndromes (important predictors of
resistance to treatment) (Semah et al., 1998; Stephen et al., 2001)
is largely unknown and neuropathology rarely available. Despite
secular changes and changing populations, historical cohorts with
lifelong observation in conjunction with post-mortem examination
can provide new insights into the long-term outcome of chronic
epilepsy.
The Epilepsy Society (www.epilepsysociety.org.uk) administers
the Chalfont Centre for Epilepsy. The centre was established in
1892 to provide care, accommodation and employment for people
with epilepsy (Sander et al., 1993). It was initially intended to be
self-sustaining through the work of residents; only subjects cap-
able of working were admitted. In October 1972, the admission
policy moved towards care of patients with epilepsy and additional
needs (medical or social) (Barclay, 1992). We present lifelong
follow-up of residents who died between 1989 and 2009; post-
mortem data were available for half. This cohort witnessed the
evolution of social and medical management of epilepsy and
thus society’s perception of people with epilepsy over the past
century. This cohort, although inevitably selected, also provides
a unique insight into long-term outcome for subjects with chronic
epilepsy in terms of life expectancy, causes of death and evolution
of seizures over a lifetime, correlated with brain and body
pathology.
Materials and methods
The study was approved by the institutional Ethics Committee. All
individuals who had post-mortem examination had era-appropriate
consent for post-mortem examination and retention of tissue for re-
search; next-of-kin or legal guardian consent was obtained. Relatives
or next-of-kin were asked for permission for post-mortem examination
for every person dying in this period, unless there were important
social considerations.
We collected data of all residents who died between 1989 (when
systematic efforts to obtain post-mortem started) and 2009 and stu-
died their life-long evolution. As the post-mortem subgroup had the
most complete overall data set (including brain examination), we used
all data of those who had post-mortem to analyse predictors of
outcome.
Clinical data
Institutional policies ensured comprehensive daily seizure recording
(Fig. 1). Average seizure frequency was arbitrarily categorized yearly
as 44 seizures/month, 1–4 seizures/month, or 51 seizure/month.
Remission was defined as at least 2 years seizure-free. Medical records
were reviewed critically; seizure and syndrome classification was based
on clinical description, EEG, neuroimaging, and additional relevant in-
vestigations according to the latest International League Against
Epilepsy (ILAE) systems (Engel, 2001; Berg et al., 2010). Residents
with cognitive decline in whom dementia was suspected had neurop-
sychometric assessment. Subjects with longstanding severe intellectual
disability without terminal cognitive decline were not considered as
having dementia.
Pathology
Formalin-fixed post-mortem whole brains were sliced coronally along
the antero-posterior axis. Each slice was examined for macroscopic
abnormalities. Systematic histological examination used 5 mm thick
blocks taken from the following regions where possible: frontal, par-
ietal, temporal and occipital cortex, insula, cingulum, cerebellum,
hippocampus, amygdala, thalamus, basal ganglia, midbrain, pons, me-
dulla and cervical spinal cord. Brains removed at post-mortem were
immediately fixed in 10% formalin and suspended. Formalin was
changed after 24 h and brains were then fixed for a minimum
period of two more weeks. Following fixation, coronal slices were
examined at 5–10 mm intervals. In addition to histological sampling
of any identified macroscopic abnormality, or presumed electroclinical
focus for the onset of seizures, a standard sampling protocol was used,
sampling tissue blocks of the hippocampus (usually at two coronal
levels), amygdala, superior temporal gyrus, parahippocampal gyrus,
anterior frontal (F1/F2), fronto-basal, cingulate, parietal and calcarine
cortex. In addition the basal ganglia, thalamus, cerebellum, brainstem
and spinal cord, from both left and right sides available, were exam-
ined. Tissue blocks were routinely processed, and embedded in
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Figure 1 An early seizure chart of an individual admitted on 25 May 1926 and started on bromide on his admission; phenobarbital was
added to his regimen on 5 June. The white pennant represents daytime, the dark pennant, night-time. Each seizure was recorded with a
mark (‘x’ or ‘/’ or ‘.’) according to severity. Note that seizure classifications varied over the years.
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paraffin. In all cases, 5 mm sections were stained with haemotoxylin
and eosin and, in the majority of blocks, with additional Luxol Fast
blue/cresyl violet. The immunohistochemistry selected for each case
varied according to the underlying pathology, but most commonly
used markers included antibodies against glial fibrillary acidic protein
(GFAP; 1:1500, polyclonal; Dako), CD68 (1:100, monoclonal; Dako;
heat pretreatment), neurofilaments [both 1:500; Sternberger
Monoclonals (SMI32&31)], dynorphin (1:100; AbD Serotec) and phos-
phorylated tau protein (1:1200, monoclonal antibody AT8;
Innogenetics, Autogen Bioclear), on 8–14mm sections.
The qualitative assessment of hippocampal sclerosis at post-mortem
has been previously validated in a stereological study (Thom et al.,
2005). Dynorphin immunohistochemistry for confirmation of epilepsy-
specific mossy fibre sprouting was carried out in the majority of cases
with hippocampal sclerosis (Thom et al., 2009). Pathological evidence
of old traumatic brain injury, for example old cortical contusions or
subdural haematoma, was recorded based on macroscopic and histo-
logical sections. The presence of cerebrovascular disease of all types
(degenerative small vessel white matter disease, regional cortical in-
farction, and spontaneous cerebral haemorrhage or lacunar infarcts)
was noted. The presence of atheroma in the main cerebral vessels
alone was not regarded as sufficient for a diagnosis of cerebrovascular
disease. In cases with suspected neurodegenerative diseases, appropri-
ate immunohistochemistry for abnormal neuronal inclusions and pro-
tein accumulation, including ubiquitin, phosphorylated tau protein,
alpha-synuclein and bA4 amyloid staining, was carried out.
We also integrated pathological data from previous studies [for hip-
pocampal sclerosis (Thom et al., 2009), and Dravet syndrome
(Catarino et al., 2011)] and used the same unified subject numbering
system, allowing correlation of different aspects across publications
(Thom et al., 2005, 2012; Liu et al., 2012; Martinian et al., 2012).
A brain structural abnormality (including stroke or traumatic lesions)
seen at post-mortem was considered the presumed cause of epilepsy if
in keeping with clinical and paraclinical data. Macroscopic body post-
mortem examination was performed and abnormalities were further
studied histologically. Sudden unexpected death in epilepsy (SUDEP)
was defined as death in which no cause was found at autopsy (i.e.
requiring post-mortem examination), occurring in benign conditions,
without evidence of status epilepticus or traumatic event (Nashef
et al., 2012).
Statistics
Chi-squared, Fisher’s exact, Kruskal-Wallis and Mann-Whitney tests
were used as appropriate in univariate analyses. Multivariate regression
analyses of age at death (i.e. length of life) were performed using a
backward-stepwise approach first entering all factors that had P4 0.1
in univariate analyses. The assumptions of multiple regression (nor-
mally-distributed residuals) were checked. Logistic regression analysis
using a similar modelling strategy was used to investigate factors asso-
ciated with the binary outcome, terminal remission. Analyses were
conducted using SPSS version 20 (SPSS Inc.) or Stata (v10; Statacorp
Inc.).
Results
Demographic and clinical data
Between 1989 and 2009, 235 residents died; 122 (52%) had post-
mortem examination, all with brain autopsy (10 had no
microscopic examination); in seven, autopsy was limited to the
brain. Comparison of characteristics of subjects who had post-
mortem examination with those who did not showed no signifi-
cant differences for gender, age at death, epilepsy duration, age at
admission, year of admission, length of residence, number of anti-
epileptic drugs tried, proportion of generalized versus focal epi-
lepsy, episodes of status epilepticus, learning disabilities, transient
episodes of remission, or terminal remission. Although there was
marked variability in the distribution of seizure frequency category
between subjects who had a post-mortem examination and those
who did not (51 seizure per month: 35% versus 13%, 1–4 seiz-
ures per months: 34% versus 61%, 44 seizures per month: 31%
versus 25%, P50.0001), there was no linear trend (P = 0.395);
the differences are not meaningful. Detailed demographic, clinical
and pathological data of subjects who had post-mortem examin-
ation are given in Table 1.
Fifty-two subjects (43%) were admitted after October 1972
(admission policy change date); they were older on admission,
had more frequent seizures and more frequently had intellectual
disability, multiple seizures types (54), a genetic cause, general-
ized epilepsy and degenerative disease (Table 1).
In subjects having post-mortem examination, 45 had an MRI
brain scan, and 43 had a CT scan; 14 had both. Median year of
MRI scan was 1997 (range 1990–2001). MRI scanning (1.5 T) was
set up at the Chalfont Centre in late 1995. The proportion of
subjects who had MRI was mostly a matter of availability; most
subjects who died after 1995 had had a pre-mortem MRI scan
(42/69, 61%), whereas subjects who died in 1995 or earlier rarely
had an MRI scan (3/53, 6%, P50.0001). Subjects admitted
before 1972 tried fewer antiepileptic drugs (fewer were available).
With one exception, all subjects were treated at some point with
at least one enzyme-inducing anti-epileptic drug.
Two subjects had underlying genetic causes confirmed (one
Unverricht-Lundborg disease, one Dravet syndrome). Six had a
clinically-suspected genetic cause for their epilepsy: Dravet syn-
drome was suspected in two, dentatorubral-pallidoluysian atrophy
in two, familial Alzheimer’s disease (with Alzheimer pathology) in
one and neuroacanthocytosis in one. Fourteen other subjects had
potential genetic causes for epilepsy based on presence of add-
itional somatic malformations, family history, bilateral cortical mal-
formation or facial dysmorphism.
Pathology
Causes of death are detailed in Table 1 for subjects who had post-
mortem examination. Thirty-five patients (29%) died suddenly,
but 14 of these—who might otherwise have had a diagnosis of
SUDEP—were shown at post-mortem to have probable cardiovas-
cular causes of death. Subjects admitted before October 1972 died
less frequently of SUDEP and more frequently of pneumonia (both
diagnosed at post-mortem examination). A structural abnormality
presumably accounting for epilepsy was found in 86 subjects
(70%). Of the 45 subjects that had MRI scans, 14 had no relevant
abnormality at post-mortem examination; only one was found to
have a structural abnormality (hippocampal sclerosis) at MRI scan
not confirmed at post-mortem examination (post-mortem exam-
ination results were considered as reference). Of those who had
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structural abnormalities at post-mortem examination (n = 32), the
abnormalities were not seen on pre-mortem MRI in 14 (45%).
Structural abnormalities found on neuropathology and not seen
on pre-mortem brain MRI were hippocampal sclerosis (10;
71%), cortical malformation (3; 21%) and one degenerative con-
dition (7%).
Hippocampal sclerosis was the most common pathology con-
sidered capable of causing seizures (45% of all cases); 30 cases
with hippocampal sclerosis had a clinical picture compatible with
mesial temporal lobe epilepsy. Structural abnormalities are detailed
in Table 1. Three had post-mortem findings suggesting an unsus-
pected genetic cause: tuberous sclerosis in two, and neurodegen-
eration with brain iron accumulation type 1 in one. The following
pathologies were labelled degenerative, irrespective of whether
they were considered the cause of the epilepsy or not: neuritic
plaques and/or neurofibrillary tangles (sometimes in the
Alzheimer’s disease spectrum), found in 26 subjects; tauopathies,
found in two subjects; ubiquitin inclusions, found in one subject;
intranuclear hyaline inclusions (one subject) and Lewy bodies
(mainly brainstem, one subject). These changes were noted only
on post-mortem and would not have been visible on MRI. One or
more lesions not presumed to be the cause of epilepsy were found
in 68 subjects (56%); 20 (29%) had traumatic lesions, 45 (66%)
ischaemic lesions, and 31 (45%) degenerative lesions.
Seizure evolution and remission
In the whole cohort (n = 235), median duration of residential care
was 29 years (range: 2 months to 72 years). During follow-up,
most subjects (175/235, 74%) had lifelong seizures with overall
stable seizure frequency (no switching between seizure-frequency
categories). Thirty-five (15%) experienced at least one period of
relapsing remission [median: one remission (range: 1–3), median
remission length for all remissions: 4 years (range: 2–28 years)].
Thirty-nine (17%) went into remission without further relapse until
death (‘terminal’ remission). Median duration of terminal remission
was 6 years (range 2–41 years) with median age of terminal re-
mission onset of 67 (33–92 years). Most subjects (25/39, 64%) in
terminal remission at death had no previous remission. The
proportion of subjects in terminal remission increased with age
(Fig. 2).
Among subjects who had post-mortem examination, established
already as representative of the whole cohort, 26 (21%) entered
terminal remission; of those (22/26, 85%) had their last medica-
tion change more than a year (median 5 years) before onset of
terminal remission. For subjects with earlier relapsing remissions,
most drug changes occurred significantly closer to the remission
[within a year in 52%; P = 0.005 (36% within 6 months)]. The
eight subjects in terminal remission with previous remissions were
not significantly different from those with earlier remission periods
but no terminal remission, in terms of the number of earlier per-
iods of remission (median 1 versus 2 years, P = 0.17), longest ear-
lier remission (median 3 versus 5 years, P = 0.2) and total time in
earlier remission (median 8 versus 6 years, P = 0.81). Univariate
and multivariate predictors of terminal remission in subjects with
post-mortem examination are shown in Table 2. In subjects
admitted before October 1972, older age at death andT
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degenerative changes not thought to be the cause of epilepsy
were independent predictors of terminal remission (data not
shown). Only three subjects admitted after 1972 went into ter-
minal remission (predictors in the whole cohort can be found in
Supplementary material). In two subjects who had no previous
period of remission and who went into spontaneous terminal re-
mission, post-mortem examination showed lacunar infarctions in
periventricular heterotopia (Fig. 3). Degenerative changes thought
not to be the cause of epilepsy were not associated with clinical
dementia (26%, P = 0.39).
Mortality
Age at death in the whole cohort showed a bimodal distribution
with a first peak 45–50 years (early mortality in comparison with
the general population) and a second at 70–85 years (Fig. 4).
Among subjects who had post-mortem examination, those
admitted after October 1972 died younger (Table 1). Death as a
direct consequence of seizures was rare (gastric aspiration in two
and traumatic intracranial haemorrhage in one). SUDEP, more fre-
quent in subjects dying aged 563 years (the median age of
death), did not entirely explain early mortality (Fig. 1). Age of
death was similar for those who died of cardiovascular causes
(n = 40), respiratory causes (n = 40) and other causes excluding
epilepsy-related deaths (n = 18; P = 0.26). Univariate and multi-
variate predictors of age at death are shown in Table 2 for the
cohort with post-mortem and for subjects with post-mortem who
died from causes other than SUDEP or seizure-related death.
Genetic cause had the strongest effect with an adjusted mean
difference in length of life of 21 years (Table 2). Pathologically
diagnosed underlying causes were not independent predictors of
early mortality. Presence of comorbidity at admission did not pre-
dict age of death. Higher seizure frequency was an independent
predictor of earlier age of death for subjects admitted before or
after 1972 analysed as separate groups (predictors in the whole
cohort can be found in Supplementary material). Considering all
individuals with potential underlying genetic conditions, genetic
cause still represented the strongest predictor of age at death
when excluding SUDEP and seizure-related deaths (data not
shown). Higher seizure frequency was associated with earlier
death with adjusted mean difference of 18 years between those
with 51 and 44 seizures/month, including all deaths (Table 2).
Discussion
The Chalfont Centre was founded during an era when the position
of subjects with epilepsy in society was particularly difficult
(Barclay, 1992; Sander et al., 1993; Duncan and Faulkner, 2003;
Shorvon, 2011). In late Victorian industrialized society, people
with epilepsy struggled immensely to find employment and hous-
ing due to stigma associated with the condition. They often ended
up in workhouses or psychiatric asylums. It became increasingly
recognized by philanthropists and physicians treating epilepsy that
another solution had to be found particularly for so-called ‘sane
epileptics’ (Lannon, 2002). Eugenicist ideas were also widely
embraced (Llewellyn, 1998); it was feared that ‘unfit’ subjects
(including those with epilepsy) (Norrgard, 2008) were having the
largest families because of indiscriminate charity work that could
endanger the survival of the ‘fittest’ individuals. Establishing an
isolated, self-financing, agricultural ‘colony’ away from the hustle
and bustle of the cities where people with epilepsy could work,
providing them with ‘healthy occupation’ seemed the ideal
Victorian solution. From a research perspective it could be specu-
lated that it was felt that the ‘colony’ was likely to provide valu-
able insights into epilepsy, with a cohort that could be closely
followed and investigated (Sander et al., 1993). In 1892, a college
of consultants from the National Hospital for the Paralysed and
Epileptics in Queen Square, London together with the Lady
Samaritans Society of the hospital founded the National Society
for Employment of Epileptics (NSEE). It was soon established in the
countryside west of London near Chalfont-St-Peter. The ‘colony’
progressively grew, hosting subjects employed in various occupa-
tions such as tailors, farmers, carpenters, ironworkers or brick-
makers. The number of ‘colonists’ reached 524 in the early
1950s. With improving understanding and treatment of epilepsy,
institutions hosting residents were increasingly felt to be old-fash-
ioned and segregational as highlighted in the Reid report (1969).
The colony began a conversion into a centre specializing in the
assessment of subjects with epilepsy. From 1972 onward, long-
term admission policies changed towards residential care of sub-
jects having epilepsy associated with other conditions. Admission
of patients with epilepsy having either another medical condition,
Figure 2 Proportion of subjects in terminal remission according
to their age at death in the whole cohort (235 subjects). Light
grey columns represent subjects that continued to experience
seizures until their death and dark grey columns represent sub-
jects in final remission at their death; scale on left is number of
subjects. Darkest grey columns represent subjects who went
into terminal remission and had post-mortem examination.
The black dotted line represents the percentage of subjects in
terminal remission at each decade (not cumulative) (scale on
the right).
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or intellectually or physically disabled, was favoured. A rehabilita-
tion unit was set up, allowing comprehensive assessment (medical
and social) of subjects with epilepsy during shorter stays.
Our cohort witnesses this evolution; it consists of two popula-
tions nowadays encountered in different settings; subjects who
would probably be independent in the community (admitted for
employment, 57%) and subjects needing institutional care or sup-
ported living (admitted for care). Subjects admitted before
October 1972 (before admission policy changes) had milder epi-
lepsy and the proportion with intellectual disabilities was closer to
that in subjects with epilepsy living independently nowadays
(Hitiris et al., 2007). The frequency of remissions was very similar
to that reported in outpatients of tertiary centre settings currently
(Neligan et al., 2011b), as was the proportion with symptomatic
(structural/metabolic) epilepsy [69% in our cohort versus 65–71%
(Semah et al., 1998; Stephen et al., 2001)], and the distribution of
presumed causes (Semah et al., 1998; Stephen et al., 2001). Some
underlying abnormalities (such as cortical malformations) were
more frequent in our post-mortem cohort than in imaging-based
studies (Semah et al., 1998; Stephen et al., 2001). Subjects
admitted later had more severe epilepsy, more genetic disease,
some had degenerative disease and the proportion with intellec-
tual disability was close to that in subjects in other institutions
(Iivanainen and Lehtinen, 1979). The heterogeneity of our
cohort allows exploration of long-term outcome in a wide spec-
trum of epilepsies. All individuals in our cohort had, at some point,
drug-resistant epilepsy according to the definition of the ILAE
(Kwan et al., 2010), but would be better described as having
chronic epilepsy, as a third had prolonged periods of remission.
Mortality at the centre is closely monitored and reviewed; there
was no secular change between 1896 and 1990 despite treatment
evolution (Klenerman et al., 1993; O’Donoghue and Sander,
Table 2 Predictors of terminal remission and length of life/age at death with unadjusted and adjusted estimates
A. Terminal remission
Predictors Unadjusted Adjusted
Odds ratio 95% Confidence
interval
Odds ratio 95% Confidence
interval
P-Value
Age at death (years) 1.12 1.06, 1.18 1.13 1.06, 1.20 50.0001
Intellectual disabilities (yes/no) 0.28 0.06, 1.28
Seizure frequency (compared with 51 seizure/month)
1–4 seizures monthly 0.43 0.16, 1.15
44 seizures monthly 0.07 0.02, 0.36
Episode(s) of status epilepticus (yes/no) 0.24 0.05, 1.07
Hippocampal sclerosis at PM (yes/no) 0.46 0.18, 1.17 0.11 0.03, 0.42 0.001
Degenerative changes at PM (not causal - yes/no) 8.64 3.30. 22.6 7.14 1.95, 26.2 0.003
B. Age at death (length of life)
Predictors Unadjusted Adjusted
Coefficient 95% Confidence
interval
Regression
Coefficient
95% Confidence
interval
P-Value
i All cases (with post-mortem examination)
Hippocampal sclerosis (yes/no) 8.4 2.1, 14.7
Underlying degenerative condition (yes/no) 18.6 34.4, 2.8
Underlying genetic condition (yes/no) 17.8 28.5, 7.1 12.9 22.17, 3.63 0.007
Intellectual disabilities (yes/no) 16.3 23.8, 8.8 11.8 18.6, 5.1 0.001
Generalized epilepsy (yes/no) 13.3 22.8, 3.9
Multiple seizure types (54) (yes/no) 14.4 28.0, 0.9
Seizure frequency (reference group 51 per month) 50.0001
1–4 seizures monthly 6.9 14.0, 0.1 7.1 13.6, 0.7
`4 seizures monthly 20.3 27.3, 13.4 18.4 24.9, 12.0
Episode(s) of status epilepticus 6.6 14.2, 1.1
ii Excluding SUDEP and epilepsy-related deaths
Older age at epilepsy onset (years) 0.36 0.7, 0.0
Hippocampal sclerosis (yes/no) 5.95 0.3, 12.2
Underlying degenerative condition (yes/no) 23.26 36.8, 9,7
Underlying genetic condition (yes/no) 23.06 31.9, 14.2 20.98 29.3, 12.7 50.0001
Intellectual disabilities (yes/no) 10.7 19.0, 2.4
Generalized epilepsy (yes/no) 13.78 23.8, 3.7
Seizure frequency (reference group 51 per month) 0.0006
1–4 seizures monthly 4.14 11.1, 2.8 3.87 10.1, 2.4
`4 seizures monthly 14.76 21.9, 7.6 12.84 19.3, 6.4
Episode(s) of status epilepticus (yes/no) 7.29 14.8, 0.3
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1997). In the two contrasting populations investigated here
(‘early’ versus ‘later’ residents), the same findings of early mortal-
ity or terminal remission emerged, suggesting that the predictors
found in this study are not specific only to a highly-selected popu-
lation with severe epilepsy (i.e. the ‘later’ residents). In this con-
text, we note that the overall prognosis of chronic epilepsy has not
dramatically changed in recent years; new anti-epileptic drugs
have not significantly increased the proportion of subjects in re-
mission (Stephen et al., 2012) and only a minority of patients with
drug-resistant epilepsy are suitable for curative surgery (Engel
et al., 2008).
The lifelong follow-up of this large cohort of subjects with
chronic epilepsy showed a biphasic evolution of epilepsy. There
was a peak of premature mortality at 45–50 years, followed
by an increasing likelihood of terminal remission in those who
survived this first peak of mortality. Terminal remissions were
not associated with a previous pattern of remission and relapse.
In contrast to previous relapsing remissions, terminal remissions
were not linked in time with changes of medication. They were
associated only with older age and degenerative changes (that
were not the cause of the epilepsy) seen at post-mortem.
Higher seizure frequency was associated with younger age at
death (remotely from epilepsy onset) even when definite SUDEP
(i.e. confirmed by negative post-mortem examination) as a cause
of death was formally excluded; the highest seizure frequency
shortened life on average by 18 years. Previous reports showing
a peak of mortality between 10 and 20 years after epilepsy onset
(Hauser et al., 1980; Lindsten et al., 2000; Lhatoo et al., 2001;
Camfield et al., 2002) did not have post-mortem data for a formal
diagnosis of definite SUDEP.
Subjects with post-mortem examination were not significantly
different from others; the main findings were similar to those from
the whole cohort, but more complete data were available in sub-
jects with post-mortem examination. Post-mortem examination
also allowed a detailed determination of risk factors for epilepsy
and cause of death. Judged against post-mortem examination,
MRI brain scanning (at 1.5 T) had a relatively low rate of false
positivity of 7%, but the rate of false negativity rose to 45%.
Among 11 subjects with an underlying genetic condition, three
(27%) were only identified at post-mortem examination, without
any pre-mortem indication of the diagnosis. In sudden death cases
that would have been diagnosed clinically as probable SUDEP
(Nashef et al., 2012), post-mortem examination revealed a differ-
ent cause of death (cardiovascular) in 40% of cases. Post-mortem
examination also allowed sensitive identification of degenerative
changes that were not apparent clinically, for example they may
not have been accompanied by cognitive decline (in 74% of
cases). Post-mortem examination therefore provided a sensitive
Figure 3 Brain post-mortem examination of a subject (Patient EP255) with lifelong partial seizures who became spontaneously seizure-
free, entering terminal remission 4 years before his death at the age of 69 years, without any relevant drug change. Macroscopic
examination (a) showed periventricular nodular heterotopia around the right temporal horn of the lateral ventricle (arrow); microscopic
examination (b) of the heterotopia showed foci of lacunar infarction (arrow), and further examination of this area (c) showed that this
infarction was chronic and organizing with macrophage infiltration and new vessel formation. Scale bars: a = 1 cm, b = 5 mm, c = 100mm.
Figure 4 Distribution of age of death, in 4-year epochs, of all
those who died whilst residents at the Chalfont Centre between
1988 and 2009. The frequency is displayed in number of cases.
Light grey columns represent the number of subjects who did
not have a post-mortem examination, all others had post-
mortem examination; dark grey columns show those who died
of SUDEP and medium grey columns show those who died of
other causes determined at post-mortem examination. The
superimposed black line (scale on right) shows the distribution of
age of death in the general population in the UK in the median
year of death (1997) (Office for National Statistics UK.
http://www.ons.gov.uk/ons/publications/re-reference-tables.
html?edition=tcm%3A77-240172).
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and valuable complement to clinical data in terms of epilepsy
causes, occurrence of secondary lesions, and causes of death,
and adds important information to our analysis.
Mortality
We found a bimodal distribution of age at death. Early mortality in
the community is mostly related to the underlying presumed cause
of epilepsy (Neligan et al., 2010); this was not the explanation
here as subjects with sinister underlying conditions were not
admitted as long-term residents for employment (Fig. 5). SUDEP
is a major contributor to the early mortality of chronic epilepsy
(Nashef et al., 1995), and it was the second most common cause
of death. Post-mortem confirmed (i.e. definite) SUDEP was only
responsible for some of the early deaths, suggesting that epilepsy
can also lead to premature death through other mechanisms.
Those who died of causes other than SUDEP or directly from
epilepsy-related deaths had similar age of death for cardiovascular,
respiratory or other causes, suggesting that no single cause was
responsible for earlier deaths; this accords with reports showing
that long-term excess mortality rates are seemingly not directly
related to the disease (Neligan et al., 2011a). Disease severity
(as measured by seizure frequency) was a major predictor of
age of death in non-epilepsy related deaths as diagnosed at
post-mortem, suggesting that co-morbidities (or their conse-
quences) may be linked with epilepsy severity. Furthermore, the
effect of disease severity seems not to be due to the presence of
somatic co-morbidities present early in the course of the disease,
as higher prevalence of somatic co-morbidities at admission was
not a predictor of age at death. Treatment seems not to be an
obvious bias; there was no disparity in terms of exposure to
enzyme-inducing anti-epileptic drugs (shown to increase the risk
for cardiovascular disease) (Mintzer et al., 2009), although sub-
jects with more severe epilepsy were exposed to a higher number
of different treatments. The higher burden of somatic co-morbid-
ity in subjects with epilepsy (Gaitatzis et al., 2004a, 2012; Tellez-
Zenteno et al., 2005) could conceivably be worsened by more
severe disease. A common genetic predisposition to epilepsy and
co-morbid conditions may also be postulated (Kasperaviciute
et al., 2011), as an underlying genetic causation was a major
predictor of early death (Table 2).
Our results suggest that drug changes might decrease the early
mortality by reducing the seizure frequency, supporting the view
that a reduction of seizure frequency is worthwhile even when
seizure-freedom cannot be achieved (Kwan et al., 2010). Our
findings also suggest that the general health of subjects with
severe epilepsy needs careful attention.
Remission
The disease burden (in term of seizures) appeared to decline as
increasing numbers of subjects went into terminal remission with
ageing, among those who survived, who generally had less severe
epilepsy. Transient periods of remission are well described in drug-
resistant epilepsy, usually, though not exclusively (Callaghan et al.,
2007; Wang et al., 2013), linked to treatment changes (Luciano
and Shorvon, 2007; Callaghan et al., 2011; Neligan et al., 2011b).
Terminal remission in our cohort seemed to be a distinct phenom-
enon, not being directly related to treatment changes and not
preceded by previous remission in most subjects. Terminal remis-
sions were all of sufficient length as to be considered not just due
to chance, adapting a recently suggested rule for use after inter-
ventions (Brandon Westover et al., 2012). Seemingly spontaneous
remissions have been reported in elderly subjects who had previ-
ously had lifelong intractable seizures (Cockerell et al., 1995),
designated at the time as ‘burned-out’ epilepsies. Although
terminal remissions appeared not to be directly triggered by treat-
ment change, a previous study from our institution showed that
withdrawing anti-epileptic drugs frequently led to relapse (Koepp
et al., 2008), suggesting that perhaps the epilepsy became drug-
sensitive, in line with evidence showing that response to medica-
tion increases with ageing (Stephen et al., 2006).
Terminal remission seemed partly related to ageing, as older
age, and degenerative changes (that were not the cause of epi-
lepsy) determined at post-mortem examination (and possibly
occurring after the onset of epilepsy), were independent pre-
dictors. These findings are compatible with epidemiological evi-
dence of a prevalence of epilepsy in the elderly that is the same
as in the general population despite a significantly increased inci-
dence (Faught et al., 2012), suggesting that elderly subjects with
epilepsy have either an increased early mortality or a higher pro-
portion of terminal remission (resolution) (Berg, 2012). Ageing
(such as neuronal loss or dysfunction, degenerative changes)
may affect the epileptogenic tissue, possibly decreasing the
burden of epileptogenic neurons (Sen et al., 2007). Ageing was
also shown to be a protective factor against epilepsy in subjects
with Alzheimer’s disease, as the risk of developing epilepsy
decreased with increasing age in Alzheimer’s disease (Amatniek
Figure 5 Chalfont residents at work (circa 1920–1940). The photographs, courtesy of the Epilepsy Society, show that residents admitted
before 1972 were typically otherwise healthy young subjects and were employed in efforts such as harvesting.
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et al., 2006). Degenerative changes (that were not the cause of
epilepsy) had a synergistic effect with ageing. The range of diag-
noses for the degenerative changes was wide. We chose not to
use Braak staging to stratify degenerative changes as tau protein
accumulation in epilepsy is not exclusively related to Alzheimer’s
disease, but also seen for example with traumatic brain injuries
(Thom et al., 2011). Two individuals who went into spontaneous
remission were found to have lacunar infarctions in the presumed
epileptogenic tissue. This may have been relevant to the occur-
rence of spontaneous remission, but the very small number of
cases does not allow us to conclude that lacunar infarctions con-
tribute more generally to spontaneous remission outside these par-
ticular cases. Subjects with hippocampal sclerosis were less likely to
have terminal remission. Whether this relates to hippocampal
sclerosis specifically, or more widely to ‘hippocampal’ rather than
neocortical epilepsy, is unclear. Animal studies show that the
hippocampus continues to generate new neurons in adulthood
(Kempermann et al., 2000), a process enhanced by seizures
(Parent et al., 1997), possibly counterbalancing the loss of epi-
leptogenic neurons occurring with age. Degenerative changes
may also increase the overall excitability of hippocampal circuitry
(Noebels, 2011). The next step would be to compare in detail the
brain pathology of subjects in this cohort who died after lifelong
seizures with those who died at comparable ages, but in terminal
remission. This could identify new pathways or potential targets in
the treatment of drug-resistant epilepsy.
This study is limited by its selected, heterogeneous and retro-
spective nature. Only subjects who died whilst residents at the
Chalfont Centre for Epilepsy were included, and thus not con-
sidered were subjects discharged (having probably improved
during their stay), potentially overestimating the importance of
the identified early peak of mortality, but also possibly underesti-
mating the proportion of subjects entering terminal remission later.
The two contrasting populations differed by institutional admission
criteria over the two distinct historical periods, and cannot there-
fore be used to provide insight into temporal changes in epilepsy
over the whole duration of the study. Because of secular changes
in seizure nomenclature and descriptions, it was not possible to
assess the importance (e.g. proportion) of individual seizure types,
known to be an important factor in SUDEP (Nashef et al., 1995).
Historical data also did not allow the use of current criteria in
terms of syndromic diagnosis, whilst for example video telemetry
and multimodal imaging could now determine more reliably the
relation between cerebral lesion and seizures. The available MRI
data also would not today be considered state-of-the-art.
Despite being selected, this historical cohort provides valuable
insights into the long-term outcome of epilepsy. Epilepsy severity
appears to be a major factor influencing life expectancy of subjects
with chronic epilepsy even when excluding epilepsy-related
deaths. With ageing, the disease tended to improve, possibly
becoming drug-responsive (Liu et al., 2012).
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